CTOs on the Move

Alivia Technology

www.aliviatechnology.com

 
We launched Absolute Insight in 2016 to empower business users in the healthcare sector, where our clients have used it to alleviate the opioid crisis, curb waste in the healthcare system, and target fraudulent entities. As an industry agnostic platform, we`ve began to expand our service across other verticals, fulfilling our mission to become the global gateway for business users to leverage advanced analytics and artificial intelligence at scale. With a deep understanding of your company`s pain points and a platform that makes advanced analytics truly easy, your business users can create data-driven actionable insights and automated pipelines. As data continues ...
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Similar Companies

Hero

Hero was founded to be the world`s most people-focused healthcare company by creating frictionless solutions to the most challenging problems facing patients and caregivers.

Curaleaf

Curaleaf (CSE: CURA) is a leading vertically integrated cannabis operator in the United States. Headquartered in Wakefield, Massachusetts, Curaleaf is located in 10 states and owns and operates 26 dispensaries, 10 cultivation sites and 9 processing sites with a focus on highly populated, limited license states, including Florida, Massachusetts, New Jersey and New York. Here at Curaleaf, we leverage our extensive research and development capabilities to distribute cannabis products in multiple formats with the highest standard for safety, effectiveness, consistent quality and customer care. We are committed to being the industry`s leading resource in education and advancement through research and advocacy, and our Florida operations were the first in the cannabis industry to receive the Safe Quality Food certification under the Global Food Safety Initiative, setting a new standard of excellence. Our Curaleaf network of operating companies collectively employs a national workforce of over 500 people. Plans for additional growth are actively in place.

Kolmar Laboratories Inc

Kolmar Laboratories Inc is one of the leading companies in Healthcare, Pharmaceuticals, and Biotech industry. Kolmar Laboratories Inc is based in Port Jervis, NY. You can find more information on Kolmar Laboratories Inc at www.kolmar.com

Hims and Hers

Hims & Hers is a consumer-first platform transforming the way customers fulfill their health and wellness needs. Its digital platform enables access to treatments for a broad range of conditions, including those related to sexual health, hair loss, dermatology, mental health and primary care. Hims & Hers connects patients to licensed healthcare professionals who can prescribe medications when appropriate. Prescriptions are fulfilled online through licensed pharmacies on a subscription basis, making accessing treatments simple, affordable, and straightforward. Through the Hims & Hers mobile apps, consumers can access a range of educational programs, wellness content, community support, and other services that promote lifelong health and wellness. Hims & Hers products can also be found in tens of thousands of top retail locations in the United States. Launched in November 2017, Hims & Hers serves the entire United States and select locations in the United Kingdom. The company is publicly traded on the New York Stock Exchange.

Kolltan

Kolltan Pharmaceuticals is a private company founded in 2007 that is developing novel monoclonal antibody (mAb) drugs targeting receptor tyrosine kinases (RTKs). Kolltan's primary targets derive from seminal discoveries made in the laboratory of Dr. Joseph Schlessinger, Chairman of the Department of Pharmacology at the Yale School of Medicine, and in Kolltan’s laboratories. Dr. Schlessinger's laboratory has characterized a novel molecular mechanism underlying activation of RTKs providing, for the first time, a clear molecular explanation — at atomic resolution — for the oncogenic activity of mutations that have been identified in a variety of human cancers.